Literature DB >> 27129694

"Watching the Detectives" report of the general assembly of the EU project DETECTIVE Brussels, 24-25 November 2015.

Mathieu Vinken1, Vera Rogiers1, Ruani N Fernando1, Umesh Chaudhari2, Sylvia E Escher3, Jan G Hengstler4, Jürgen Hescheler2, Paul Jennings5, Hector C Keun6, Jos C S Kleinjans7, Raivo Kolde8, Laxmikanth Kollipara9, Annette Kopp-Schneider10, Alice Limonciel5, Harshal Nemade2, Filomain Nguemo2, Hedi Peterson8, Pilar Prieto11, Robim M Rodrigues1, Agapios Sachinidis2, Christoph Schäfer2, Albert Sickmann9,12,13, Dimitry Spitkovsky2, Regina Stöber4, Simone G J van Breda7, Bob van de Water14, Manon Vivier1, René P Zahedi9.   

Abstract

SEURAT-1 is a joint research initiative between the European Commission and Cosmetics Europe aiming to develop in vitro- and in silico-based methods to replace the in vivo repeated dose systemic toxicity test used for the assessment of human safety. As one of the building blocks of SEURAT-1, the DETECTIVE project focused on a key element on which in vitro toxicity testing relies: the development of robust and reliable, sensitive and specific in vitro biomarkers and surrogate endpoints that can be used for safety assessments of chronically acting toxicants, relevant for humans. The work conducted by the DETECTIVE consortium partners has established a screening pipeline of functional and "-omics" technologies, including high-content and high-throughput screening platforms, to develop and investigate human biomarkers for repeated dose toxicity in cellular in vitro models. Identification and statistical selection of highly predictive biomarkers in a pathway- and evidence-based approach constitute a major step in an integrated approach towards the replacement of animal testing in human safety assessment. To discuss the final outcomes and achievements of the consortium, a meeting was organized in Brussels. This meeting brought together data-producing and supporting consortium partners. The presentations focused on the current state of ongoing and concluding projects and the strategies employed to identify new relevant biomarkers of toxicity. The outcomes and deliverables, including the dissemination of results in data-rich "-omics" databases, were discussed as were the future perspectives of the work completed under the DETECTIVE project. Although some projects were still in progress and required continued data analysis, this report summarizes the presentations, discussions and the outcomes of the project.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27129694      PMCID: PMC5435100          DOI: 10.1007/s00204-016-1719-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  30 in total

1.  Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients.

Authors:  Mathieu Vinken; Marleen Pauwels; Gamze Ates; Manon Vivier; Tamara Vanhaecke; Vera Rogiers
Journal:  Arch Toxicol       Date:  2011-10-29       Impact factor: 5.153

2.  Critical analysis of the SCCNFP/SCCP safety assessment of cosmetic ingredients (2000-2006).

Authors:  M Pauwels; B Dejaegher; Y Vander Heyden; V Rogiers
Journal:  Food Chem Toxicol       Date:  2009-04       Impact factor: 6.023

3.  Safety assessment of cosmetics in Europe. Preface.

Authors:  Vera Rogiers; Marleen Pauwels
Journal:  Curr Probl Dermatol       Date:  2008

4.  Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing.

Authors:  Alice Limonciel; Konrad Moenks; Sven Stanzel; Germaine L Truisi; Céline Parmentier; Lydia Aschauer; Anja Wilmes; Lysiane Richert; Philip Hewitt; Stefan O Mueller; Arno Lukas; Annette Kopp-Schneider; Martin O Leonard; Paul Jennings
Journal:  Toxicol In Vitro       Date:  2015-01-13       Impact factor: 3.500

5.  Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity.

Authors:  Tina C Stummann; Mario Beilmann; Göran Duker; Berengere Dumotier; J Magnus Fredriksson; Robin L Jones; Marina Hasiwa; Y James Kang; Carl-Fredrik Mandenius; Thomas Meyer; Giorgio Minotti; Y Jean-Pierre Valentin; Bernd J Zünkler; Susanne Bremer
Journal:  Cardiovasc Toxicol       Date:  2009-07-02       Impact factor: 3.231

6.  Epigenetic changes in p21 expression in renal cells after exposure to bromate.

Authors:  N E Scholpa; X Zhang; R T Kolli; B S Cummings
Journal:  Toxicol Sci       Date:  2014-07-11       Impact factor: 4.849

Review 7.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

Review 8.  Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.

Authors:  Mathieu Vinken
Journal:  Chem Res Toxicol       Date:  2015-07-02       Impact factor: 3.739

9.  Human iPSC-based cardiac microphysiological system for drug screening applications.

Authors:  Anurag Mathur; Peter Loskill; Kaifeng Shao; Nathaniel Huebsch; SoonGweon Hong; Sivan G Marcus; Natalie Marks; Mohammad Mandegar; Bruce R Conklin; Luke P Lee; Kevin E Healy
Journal:  Sci Rep       Date:  2015-03-09       Impact factor: 4.379

10.  Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.

Authors:  Umesh Chaudhari; Harshal Nemade; Vilas Wagh; John Antonydas Gaspar; James K Ellis; Sureshkumar Perumal Srinivasan; Dimitry Spitkovski; Filomain Nguemo; Jochem Louisse; Susanne Bremer; Jürgen Hescheler; Hector C Keun; Jan G Hengstler; Agapios Sachinidis
Journal:  Arch Toxicol       Date:  2015-11-04       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.